Install
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
- 391articles · 365d
- 3+ day agolatest article
- Sep 15, 2025earliest in window
- 93%with images
- 262avg words
- Economy, Business & Finance 299
- Business & Industrial 250
- Medical 239
- Health & Wellness 137
- Finance & Business 80
- Health 60
- Transportation 33
- Industrial 28
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Pharma Pulse: Bipartisan 340B Law Introduced and Peak Rock's Specialty Pharmacy Bet
2+ mon, 4+ day ago (267+ words) In this week's Pharma Pulse, lawmakers introduce comprehensive 340B legislation, Peak Rock Capital completes its acquisition of Asembia, and new LogiPharma data shows supply chain risks across the industry. Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest…...
Which US health policy will shape market access most?
3+ mon, 3+ week ago (28+ words) Pharmaceutical Commerce Trending on Pharmaceutical Commerce Pharma Pulse: The FDA Shake-Up and Growing Frustration with Prior Auth Reform...
How Direct-to-Patient is Redefining Drug Pricing
3+ mon, 3+ week ago (530+ words) The current prescription journey is not working. It is not working for patients struggling to afford vital medications. It is not working for prescribers battling complex, fragmented systems. And it is not working for manufacturers who are unable to optimize…...
How Specialty Drug Commercialization Differs in Canada from the US
4+ mon, 1+ week ago (263+ words) Pharmaceutical Commerce In the second part of her interview at Asembia AXS26 in Las Vegas, Jessica Lovett, VP of Commercial Strategy and Innovation at Innomar Strategies, outlines how manufacturers should approach early commercial planning for specialty therapies in the Canadian market....
Real-Time Intervention: The Next Evolution in Copay Oversight
5+ mon, 6+ day ago (749+ words) Industry analysis suggests that copay spending misaligned with a brand's business goals accounts for as much as $5 billion annually, with roughly 20% of copay spend driven by payer tactics, program design gaps and pharmacy-level misuse. Each of these factors widens the…...
Could Trump's New Drug Tariffs Shift Pharma Supply Chain Strategy?
5+ mon, 1+ week ago (483+ words) Pharmaceutical Commerce The Trump administrationâs April 2, 2026, announcement of a 100% base levy on imported APIs and patented drugs could redefine how the industry approaches manufacturing and commercialization. While the headline rate is substantial, the framework introduces several complex variables that…...
Op-Ed: How Rethinking Hospital Access Can Solve the American Drug Shortage
5+ mon, 2+ week ago (896+ words) To fix America's drug shortages, pharma must look beyond manufacturing and overhaul how medicines are allocated and delivered to smaller hospitals. For more than a decade, drug shortages have been treated as a manufacturing problem. When shortages occur, the conversation…...
Why Pharma Is Exploring Direct-to-Employer Benefit Models
5+ mon, 3+ week ago (350+ words) Pharmaceutical Commerce In the final installment of his three-part interview series, Jay Bregman, founder and CEO of Andel, discusses the factors contributing to pharmaceutical manufacturersâ growing interest in engaging employers more directly, as well as the potential implications for the…...
Rising GLP-1 Demand Pressures Conventional Employer Drug Benefits
5+ mon, 3+ week ago (126+ words) Jay Bregman, founder and CEO of Andel, discusses how employers are managing rising costs for prescription benefits and how pharma companies are shifting their distribution patterns. In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising…...
Exploring the Growing Affordability Crisis in Healthcare
6+ mon, 1+ week ago (424+ words) In this Q&A, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, discusses rising insurance costs, widening affordability gaps, and growing pressure on the healthcare safety net. Drawing on insights from his experience…...